Noha Elkady | Cancer Biomarkers | Research Excellence Award

Published on by Oncology

Prof. Noha Elkady | Cancer Biomarkers | Research Excellence Award 

Professor | Menofia University | Egypt

Professor Noha Mohamed Nour El-din El-Kady is a senior consultant of pathology at the Faculty of Medicine, Menoufiya University, Egypt, with an outstanding academic career spanning education, diagnostics, and research. She earned her MBBCH, MSc, and MD degrees with excellence from Menoufiya University and progressed through all academic ranks to full professorship. She has extensive teaching experience across medical and health disciplines, curriculum design, assessment, quality assurance, and postgraduate supervision. Dr. El-Kady is a highly experienced diagnostic pathologist skilled in histopathology, cytology, immunohistochemistry, and frozen sections. She has participated in more than 120 international workshops and serves as a peer reviewer for leading indexed journals, receiving an Outstanding Reviewer Award. Her research output includes over 25 publications focusing on cancer pathology, biomarkers, and tumor microenvironment. She has received multiple awards for academic excellence, research, teaching, and community service.

Citation Metrics (Google Scholar)

208
150
100
50
0

Citations

208

h-index

9

i10-index

9

Citations

h-index

i10-index

View ResearchGate Profile View Google Scholar Profile
 View LinkedIn Profile

Featured Publications


Immunohistochemical expression of cyclo-oxygenase-2 and liver X receptor-α in acne vulgaris


– Journal of Clinical and Diagnostic Research, 2017 (19 citations)

 

Hend Gamal | Cancer Biology | Young Scientist Award

Published on by Oncology

Dr. Hend Gamal | Cancer Biology | Young Scientist Award 

Academic Advisor | Fengkai Group | Egypt 

Dr. Hend Gamal is an Egyptian bio-nanotechnology researcher specializing in cancer biology, with a PhD focused on laser-activated gold nanoparticle–based photothermal therapy for breast cancer. She holds an MSc in cancer biology and a strong foundation in molecular biology, nanotechnology, animal models, and advanced imaging techniques. Her research integrates nanomedicine, photothermal/photodynamic therapies, AI, in silico methods, and CRISPR for innovative cancer treatments. Dr. Gamal has authored multiple high-impact publications in international journals and IEEE conferences, with additional contributions as a co-author and book chapter contributor. She actively serves as an academic advisor, instructor, mentor, reviewer, editorial board member, and guest editor across reputable scientific platforms. Her professional profile is strengthened by extensive workshops, certifications, and international conference presentations and invitations. Dr. Gamal has received prestigious research award nominations and continues to contribute globally to oncology, nanotechnology, and translational cancer research.

Citation Metrics (Google Scholar)

47
35
25
10
0

Citations

47

h-index

4

i10-index

2

Citations

h-index

i10-index

View ORCID Profile View Google Scholar Profile

Featured Publications


Beyond the Bacterial Microbiome: Exploring the Gut Virome and Mycobiome in Health and Disease

– Current Trends in Biomedical Engineering & Biosciences, 2025

 

Permal Deo | Prostate Cancer | Best Researcher Award

Published on by Oncology

Dr. Permal Deo | Prostate Cancer | Best Researcher Award

Senior Lecturer | Clinical and Health Sciences, University of South Australia | Australia

Dr. Permal Deo is a distinguished food scientist and academic leader renowned for his contributions to nutrition, food biochemistry, and public health research. He holds a PhD in Food Biochemistry from Queen’s University Belfast, UK, where his doctoral work investigated the effects of food-derived advanced glycation end-products (AGEs) on oxidative stress and receptor activity in human cell lines. Complementing this, he earned a Master of Applied Science and Postgraduate Diploma from The University of Queensland, Australia, and a Bachelor of Science from The University of the South Pacific, Fiji. With over two decades of academic, research, and industry experience, Dr. Deo’s expertise encompasses food microbiology, food processing, functional foods, and the molecular pathways linking type 2 diabetes and Alzheimer’s disease. His research emphasizes the bioactivity of natural plant compounds and nutraceuticals in combating oxidative stress and inflammation, as well as the antimicrobial and food safety applications of electrochemically activated solutions. An accomplished mentor and research leader, he has supervised numerous postgraduate students and attracted more than AUD 2.5 million in competitive funding from prestigious bodies including the Australian Research Council, Diabetes Australia, and Horticulture Innovation. His extensive collaborations with institutions such as CSIRO, Monash University, and the University of Adelaide have advanced understanding in genome stability, indigenous food systems, and sustainable nutrition technologies. Widely recognized for his scholarly impact and leadership, Dr. Deo has presented at global scientific conferences and published influential studies in leading journals. His enduring scientific legacy is reflected through 944 citations, 57 documents, and an h-index of 19, underscoring his influential role in advancing the frontiers of food biochemistry, nutritional science, and biomedical innovation.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Snelson, M., Tan, S. M., Clarke, R. E., De Pasquale, C., Thallas-Bonke, V., Deo, P., … & Coughlan, M. T. (2021). Processed foods drive intestinal barrier permeability and microvascular diseases. Science Advances, 7(14), eabe4841. Cited by: 148

2. Sim, D. P., Khazandi, M., Chan, W. Y., Deo, P., & Trott, D. J. (2019). Antimicrobial activity of thyme oil, oregano oil, thymol and carvacrol against sensitive and resistant microbial isolates from dogs with otitis externa. Veterinary Dermatology. Cited by: 106

3. Deo, P., Hewawasam, E., Karakoulakis, A., Claudie, D. J., Nelson, R., & Vemulpad, S. (2016). In vitro inhibitory activities of selected Australian medicinal plant extracts against protein glycation, angiotensin converting enzyme (ACE), and digestive enzymes linked to diabetes. BMC Complementary and Alternative Medicine, 16(1), 435. Cited by: 61

4. Bergamin, A., Mantzioris, E., Cross, G., Deo, P., Garg, S., & Hill, A. M. (2019). Nutraceuticals: Reviewing their role in chronic disease prevention and management. Pharmaceutical Medicine, 33(4), 291–309. Cited by: 60

5. Fenech, M., Knasmueller, S., Knudsen, L. E., Kirsch-Volders, M., Deo, P., … & Bonassi, S. (2021). “Micronuclei and Disease” special issue: Aims, scope, and synthesis of outcomes. Mutation Research/Reviews in Mutation Research, 788, 108384. Cited by: 54

6. Ferro, S., Amorico, T., & Deo, P. (2018). Role of food sanitising treatments in inducing the ‘viable but nonculturable’ state of microorganisms. Food Control, 91, 321–329. Cited by: 54

Zu-Chian Chiang | Biomedicine | Best Researcher Award

Published on by Oncology

Dr. Zu-Chian Chiang | Biomedicine | Best Researcher Award

Fujian Normal University | China

Author Profile

Scopus

🔬 Dr. Zu-Chian Chiang, Ph.D.

Postdoctoral Fellow | Biomedical Research & Targeted Cancer Therapy Specialist 🧪🧬🎯
Fujian Normal University, Biomedical Research Center of Southern China

Dr. Zu-Chian Chiang is a distinguished Postdoctoral Fellow at the Biomedical Research Center of Southern China, Fujian Normal University, Qishan Campus, in Fuzhou, China. With a strong foundation in Materials and Chemical Engineering (Ph.D., National United University, Taiwan) and Chemistry (M.S., Tunghai University, Taiwan), Dr. Chiang has dedicated his academic journey to the intersection of materials science, chemistry, and biomedical innovation.

His research interests span a broad range of cutting-edge biomedical fields, including:
🔹 Functional peptide synthesis for cancer and bone tissue applications
🔹 Development of biomicro/macro-molecular complexes for regenerative medicine
🔹 Design of Antibody Drug Conjugates (ADCs) for targeted cancer therapy
🔹 Engineering of aptamers as blockers, agonists, or antagonists in cancer treatment

💡 Dr. Chiang has also contributed to academia through teaching roles, serving as a Teaching Assistant in Organic Chemistry and Chemical Engineering Thermodynamics at National United University.

🏆 Awards & Honors

  • 2020: Science and Technology Commissioner, Quanzhou, Fujian Province

  • 2017: Chairman Award, Miaoli Southeast Rotary Club, Rotary International Taiwan

  • 2016: Biotech Elite Training Reserve Program Awardee, National Taiwan University, Ministry of Science and Technology

🌐 Professional Affiliations & Contributions

  • Peer Reviewer, International Journal of Biological Macromolecules

  • Chief Club President (CP), Miaoli Xindong Satellite Rotary Club, Rotary International District 3501

  • Committee Member, Chinese Rotary Education Foundation (West District Chapter)

  • Member, Taiwan Biochemical Society 🧬

  • Member, Chinese Chemical Society ⚗️

  • Member, Chinese Society of Cell Biology 🔬

Dr. Chiang continues to blend his expertise in chemistry and biomedical engineering to push forward translational research, particularly in the field of cancer therapeutics and regenerative biomaterials.

🛡️ Conclusion

Dr. Zu-Chian Chiang stands at the forefront of interdisciplinary biomedical research, merging materials science, chemistry, and biotechnology to pioneer novel solutions in cancer therapy and regenerative medicine. His dedication to scientific advancement, combined with his active involvement in academic, professional, and community networks, highlights his role as a passionate innovator and collaborative leader in the global biomedical field. With a strong track record and a clear vision, Dr. Chiang continues to make impactful contributions that bridge the gap between cutting-edge research and clinical application. 🌍🔬💡

📊🔬NOTABLE PUBLICATION:

1. Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer In Vitro and In Vivo

Authors: Zu-Chian Chiang*, Shan Xu, Xiangqian Zhao, Min Liu*, Jizhen Lin*, Qi Chen*
Journal: Frontiers in Oncology
Year: 2022

2. Generation and Characterization of 7DC-DM1: A Non-Cleavable CD47-Targeting Antibody–Drug Conjugate with Antitumor Effects

Authors: Zu-Chian Chiang*, Shubin Fang, Yangkun Shen, Jizhen Lin, Qi Chen
Journal: International Journal of Biological Macromolecules
Year: 2025

3. Strengthening Effect of Thalidomide Combined with Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy

Authors: Qing Liu, Zu-Chian Chiang#, Xiangxian Zhao, Dong-Ya Cui, Xinxin Li, Hao Chen, Fangyu Lin, Tao Jiang, Qi Chen, Xiaoyan Lin*
Journal: Current Pharmaceutical Biotechnology
Year: 2024

4. Preparation and Characterization of Antibody–Drug Conjugates Acting on HER2-Positive Cancer Cells

Authors: Zu-Chian Chiang, Yi-Kai Chiu, Cheng-Chung Lee, Yueh-Liang Tsou, Hong-Sen Chen, Horng-Ru Hsu, Tzung-Jie Yang
Journal: PLOS ONE
Year: 2020